173 related articles for article (PubMed ID: 25117294)
1. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
2. [Diagnosis and management of EBV-positive lymphoproliferative disorders].
Arai A
Rinsho Ketsueki; 2023; 64(8):764-771. PubMed ID: 37673629
[TBL] [Abstract][Full Text] [Related]
3. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
[TBL] [Abstract][Full Text] [Related]
4. Acquired hemophilia A associated with Epstein-Barr-virus-associated T/natural killer-cell lymphoproliferative disease: A case report.
Yamamoto M; Shindo M; Sumi C; Igarashi S; Saito T; Tsukada N; Toki Y; Hatayama M; Inamura J; Sato K; Mizukami Y; Torimoto Y; Okumura T
Medicine (Baltimore); 2021 Apr; 100(16):e25518. PubMed ID: 33879690
[TBL] [Abstract][Full Text] [Related]
5. Inherited Genetic Susceptibility to Nonimmunosuppressed Epstein-Barr Virus-associated T/NK-cell Lymphoproliferative Diseases in Chinese Patients.
Guan YQ; Shen KF; Yang L; Cai HD; Zhang ML; Wang JC; Long XL; Xiong J; Gu J; Zhang PL; Xiao M; Zhang W; Zhou JF
Curr Med Sci; 2021 Jun; 41(3):482-490. PubMed ID: 34170459
[TBL] [Abstract][Full Text] [Related]
6. Depletion of central memory CD8
Maeda Y; Wada H; Sugiyama D; Saito T; Irie T; Itahashi K; Minoura K; Suzuki S; Kojima T; Kakimi K; Nakajima J; Funakoshi T; Iida S; Oka M; Shimamura T; Doi T; Doki Y; Nakayama E; Ueda R; Nishikawa H
Nat Commun; 2021 Dec; 12(1):7280. PubMed ID: 34907192
[TBL] [Abstract][Full Text] [Related]
7. When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.
Sacco KA; Notarangelo LD; Delmonte OM
Clin Microbiol Infect; 2023 Apr; 29(4):457-462. PubMed ID: 36209991
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop.
Climent F; Nicolae A; de Leval L; Dirnhofer S; Leoncini L; Ondrejka SL; Soma L; Wotherspoon A; Zamo A; Quintanilla-Martinez L; Ng SB
Virchows Arch; 2023 Sep; 483(3):333-348. PubMed ID: 37646869
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
[TBL] [Abstract][Full Text] [Related]
10. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
Tobinai K; Takahashi T; Akinaga S
Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
[TBL] [Abstract][Full Text] [Related]
11. Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.
Hagemann UB; Gunnarsson L; Géraudie S; Scheffler U; Griep RA; Reiersen H; Duncan AR; Kiprijanov SM
PLoS One; 2014; 9(7):e103776. PubMed ID: 25080123
[TBL] [Abstract][Full Text] [Related]
12. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
[TBL] [Abstract][Full Text] [Related]
13. Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon.
Jiang TT; Kruglov O; Akilov OE
Blood Adv; 2024 May; 8(10):2384-2397. PubMed ID: 38489234
[TBL] [Abstract][Full Text] [Related]
14. EBV-Encoded MicroRNA-BART17-3p Targets DDX3X and Promotes EBV Infection in EBV-Associated T/Natural Killer-Cell Lymphoproliferative Diseases.
Jin J; Sun T; Zhang M; Cheng J; Gu J; Huang L; Xiao M; Zhou J; Luo H
Open Forum Infect Dis; 2023 Nov; 10(11):ofad516. PubMed ID: 38023563
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder.
Baiocchi RA; Ward JS; Carrodeguas L; Eisenbeis CF; Peng R; Roychowdhury S; Vourganti S; Sekula T; O'Brien M; Moeschberger M; Caligiuri MA
J Clin Invest; 2001 Sep; 108(6):887-94. PubMed ID: 11560958
[TBL] [Abstract][Full Text] [Related]
16. Examining the impact of immunosuppressive drugs on antibody-dependent cellular cytotoxicity (ADCC) of human peripheral blood natural killer (NK) cells and gamma delta (γδ) T cells.
Jalali S; Stankovic S; Westall GP; Reading PC; Sullivan LC; Brooks AG
Transpl Immunol; 2024 Feb; 82():101962. PubMed ID: 38007172
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
18. A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.
Berlato C; Khan MN; Schioppa T; Thompson R; Maniati E; Montfort A; Jangani M; Canosa M; Kulbe H; Hagemann UB; Duncan AR; Fletcher L; Wilkinson RW; Powles T; Quezada SA; Balkwill FR
J Clin Invest; 2017 Mar; 127(3):801-813. PubMed ID: 28134623
[TBL] [Abstract][Full Text] [Related]
19. Clinical features and prognosis of chronic natural killer cell lymphoproliferative disorders.
Liu DL; Wang YJ; Qian SY; Ma SS; Ding MJ; Dong M; Zhang JM; Zhang MZ; Chen QJ; Zhang XD
Hematology; 2024 Dec; 29(1):2307817. PubMed ID: 38319083
[TBL] [Abstract][Full Text] [Related]
20. BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.
Sejic N; George LC; Tierney RJ; Chang C; Kondrashova O; MacKinnon RN; Lan P; Bell AI; Lessene G; Long HM; Strasser A; Shannon-Lowe C; Kelly GL
Blood Adv; 2020 Oct; 4(19):4775-4787. PubMed ID: 33017468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
